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Position statement on cannabis:  
A step forwards
Dr Scott’s response[1] to our position statement[2] enables us to clarify 
our views to health professionals and the public.
We agree with Dr Scott on several points. There is an increasing 
evidence-based consensus that policy on alcohol, tobacco, cannabis 
and other substances should move from the ‘war on drugs’ towards 
a science-based public health approach (as was successful locally 
in addressing tobacco use).[3] We agree that various substances 
differ in their associated costs and harms and that globally alcohol 
is a far more harmful substance than cannabis.[4] We also agree 
that an approach to substances that emphasises harm reduction 
and human rights is also key, and that new local policies and 
programmes are urgently needed, given the enormous burden of 
disease caused by alcohol, tobacco, cannabis and other substance 
use.[5] Our position statement was developed with these in mind! 
We have also submitted to this journal a position statement on 
harm reduction[6] to emphasise the importance of this approach to 
alcohol, tobacco, cannabis and other substance use from a public 
health perspective.
Nevertheless, important clarifications on questions of science, 
substance use regulation and local politics are also needed.
Dr Scott claims that our scientific view has ‘confirmation 
bias’ in that we selectively present evidence on the harms of 
cannabis. However, we drew on rigorous published systematic 
reviews in discussing its harms and benefits. While we accept 
that alcohol is a harmful agent and that cannabis may have health 
benefits, systematic reviews routinely confirm that cannabis use 
is harmful for certain aspects of health. Research on its health 
benefits remains sparse to date, with more research needed 
to establish safe dosages. Health professionals and the public 
must understand what the scientific literature indicates and the 
individual and public health problems associated with the use of 
tobacco, alcohol, cannabis and other psychoactive substances. 
Awareness of the potential medicinal uses of psychoactive agents 
is also important, as is the need for further research in this area. 
Our position statement made these points and we trust that 
health professionals will be persuaded by the relevant systematic 
reviews.
Dr Scott starkly contrasts prohibition and legal regulation and 
argues that decriminalisation is merely a form of prohibition. 
Our more nuanced view is that a broad spectrum of legislation 
is consistent with the harm reduction approach. The evidence 
base indicates that decriminalisation can contribute to improved 
public health (Dr Scott mentions Portugal, but does not mention 
this finding in that context) and that legal regulation does not 
necessarily stamp out criminal activity (consider the illegal trade 
of alcohol in South Africa (SA)). [7] Decriminalisation may be 
an achievable step locally for cannabis but does not preclude 
additional types of regulation for a range of drugs over time, based 
on evidence of what works to improve public health and to reduce 
harm. We hope that policy allows research on cannabis and other 
drugs for medicinal purposes, that when people use psychoactive 
substances measures are made available to prioritise safety (e.g. 
needle exchange), and that medication-assisted treatment is 
made widely available. At the same time, we are cognisant of not 
wanting policy to lead simply to ‘Big Tobacco’ being joined by ‘Big 
Marijuana’[8] – there is insufficient evidence this would be a gain 
for public health.
Regarding politics, it is important to emphasise that our position 
statement was authored by members of the Executive Committee 
of the Central Drug Authority (CDA). The broader CDA contains 
many civil servants representing different government departments 
and reporting to their ministers, each of whom may have different 
positions on aspects of policy related to alcohol, tobacco, cannabis 
and psychoactive substance use. For example, some departments 
are focused on adhering to the international agreements that 
SA has signed to outlaw drugs. We also know that there may be 
different positions within government about the value of putting 
more pressure on the liquor industry to support harm reduction 
efforts and of doing so from a public health perspective. As advisors 
to government, our goal is to emphasise an evidence-based and 
balanced approach. We hoped that a public position statement 
would be welcomed by health professionals and the public as a 
progressive and pragmatic step to address SA’s massive public health 
problem from alcohol, tobacco, cannabis and other psychoactive 
substance use.
We did not expect that our position statement would be accepted 
by those wishing to continue a ‘war on drugs’, or by those who 
support immediate commercialisation of all psychoactive sub-
stances in SA. Our science-based public health approach attempts 
to take a balanced and pragmatic step forward. As more data 
become available and political will is found to develop new policies 
and programmes to improve public health and advance harm 
reduction with respect to the use of alcohol, tobacco, cannabis and 
other psychoactive substances, we hope that the CDA Executive 
Committee will reassess its position on the best way forward. In 
the interim, we call on health professionals, civil society and the 
public to join the move away from the ‘war on drugs’ and towards 
a public health approach. While our position statement could lead 
to a focus on the issue of cannabis decriminalisation, in line with a 
public health approach and the profile of our burden of disease, we 
request health professionals and civil society to also focus on the 
urgency for harm reduction measures in the area of alcohol, tobacco 
and opioid use.
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